quote]Christopher Missling
Thank you, Clayton. I’d like to thank everyone for joining us today’s conference call to review our financial results and clinical progress. I am pleased to have the opportunity to share our exciting accomplishments from 2017, and give you a sense of some key milestones to look forward to in 2018.
Anavex Life Sciences is a clinical stage biotechnology company, focused on developing effective targeted therapies for the treatment of neurodevelopmental and neurodegenerative diseases under the precision medicine paradigm. This entails applying to a targeted treatment approach, genomics data and algorithm analysis.[/quote]
See post 136708 by investor2014 for entire link here...
Dr. M. has been saying this for over a year that I am aware of. IMO, we have recently begun to get a better understanding of where he was leading us. His position was well before anyone understood what was going on w/FDA new guidance. In fact we still do not understand where that is going to take us. IMO, like when J. Kennedy said "we were going to the moon" in ...some time period. He did not know when or how but it serves as a useful example of what a leadership statement looks like.
IM, this is one of those moments when it becomes obvious that the FDA processes forCNS indications are not working and we have no effective substitute, yet. Dr.M, G. and others stepped in it before they really understood what the consequences were.(IMO) Dr.M. is smart enough to take the point and to say nominally what direction AVXL is heading instead of blowing our $$$ wad away. I think he has a compass and knows the WAY POINTS (Ask T-38 what that means)...he wants to fly VFR but only IFR conditions exist on departure FBO and where we are going.
I can say from experience that developing AI tolls is an iterative learning process (not same as trial and error exactly but like it). The tools will begin to present functionality which will add value quickly after conceptual stages, but they are risky to use at first. He is saying, we have knowledge on CNS RETT and we have a tool populated with what we currently know...AND...we DO KNOW WHAT WE DO NOT KNOW.
I think he is saying we know enough about RETT indication and how to treat it and to set way points. We expect the destination to be VFR when we get there and we are certain we will do no harm. Now, this kind of leadership is typically valued in low usage, small companies. Will the FDA write rules around the Beta or wait/insist they lead when we all know they are not able to???
Just my spontaneous response...attackers hold fire.
News 
Market Data 
Discover 
